Pre-made Daxdilimab benchmark antibody ( Whole mAb, anti-LILRA4/ILT7 therapeutic antibody, Anti-CD85g Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-135
Pre-Made Daxdilimab biosimilar, Whole mAb, Anti-LILRA4/ILT7 Antibody: Anti-CD85g therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Daxdilimab is a novel drug designed to target and bind to ILT7, which is a cell surface molecule specific to the pDC type of dendritic cells. It is currently being investigated against autoimmune diseases and COVID-19. and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||List Price(In USD)||Discount off||Discount Price|
Size： 1mg | 10mg | 100mg
|Products Name (INN Index)||Pre-Made Daxdilimab biosimilar, Whole mAb, Anti-LILRA4/ILT7 Antibody: Anti-CD85g therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Cutaneous lupus erythematosus;Dermatomyositis;Polymyositis;Sjogren's syndrome;Systemic lupus erythematosus;Systemic scleroderma;Acute lung injury|